375 related articles for article (PubMed ID: 31416990)
21. [Diabetes mellitus type 1 and 2. Flexible therapy with insulin degludec].
Rausch R
Med Monatsschr Pharm; 2014 Jul; 37(7):273-4. PubMed ID: 25065174
[No Abstract] [Full Text] [Related]
22. Lessons from the bedside: ketoacidosis and SGLT2 inhibitors.
Chow YY; Worsley R; Topliss DJ
Med J Aust; 2016 Aug; 205(4):191-2. PubMed ID: 27510353
[No Abstract] [Full Text] [Related]
23. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
[TBL] [Abstract][Full Text] [Related]
24. Is pramlintide an adjunct to insulin therapy?
Charles MA
Diabetes Technol Ther; 2002; 4(2):190-2. PubMed ID: 12079622
[No Abstract] [Full Text] [Related]
25. Combination therapies with insulin in type 2 diabetes.
Yki-Järvinen H
Diabetes Care; 2001 Apr; 24(4):758-67. PubMed ID: 11315844
[No Abstract] [Full Text] [Related]
26. Insulin detemir: a new basal insulin analogue.
Soran H; Younis N
Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
Miyata KN; Zhao S; Wu CH; Lo CS; Ghosh A; Chenier I; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
Diabetes Res Clin Pract; 2020 Apr; 162():108107. PubMed ID: 32173417
[TBL] [Abstract][Full Text] [Related]
28. Considerations for SGLT2 inhibitor use in post-transplantation diabetes.
Hecking M; Jenssen T
Nat Rev Nephrol; 2019 Sep; 15(9):525-526. PubMed ID: 31235880
[No Abstract] [Full Text] [Related]
29. Reduction of Severe Hypoglycemic Events Among Outpatients with Type 2 Diabetes Following Sodium-Glucose Cotransporter 2 Inhibitor Marketing in Japan.
Yamashita K; Yoshiike S; Yamashita T; Mori JI; Aizawa T
Horm Metab Res; 2022 Nov; 54(11):747-753. PubMed ID: 36027909
[TBL] [Abstract][Full Text] [Related]
30. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 inhibitors in Type 1 diabetes: is this the future?
Herring R; Russell-Jones DL
Diabet Med; 2018 Dec; 35(12):1642-1643. PubMed ID: 30091226
[No Abstract] [Full Text] [Related]
32. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges.
Blumer I; Clement M
Clin Ther; 2017 Aug; 39(8S2):S1-S11. PubMed ID: 27871780
[TBL] [Abstract][Full Text] [Related]
33. A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.
Sokolov V; Yakovleva T; Stolbov L; Penland RC; Boulton D; Parkinson J; Tang W
CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):831-841. PubMed ID: 36912425
[TBL] [Abstract][Full Text] [Related]
34. Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?
Popovic DS; Stoian AP; Papanas N
J Diabetes Complications; 2022 Nov; 36(11):108338. PubMed ID: 36240667
[No Abstract] [Full Text] [Related]
35. Emergence of promising therapies in diabetes mellitus.
Akkati S; Sam KG; Tungha G
J Clin Pharmacol; 2011 Jun; 51(6):796-804. PubMed ID: 20705952
[TBL] [Abstract][Full Text] [Related]
36. Optimizing glycemic control with insulin glargine.
Williams JB
Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
[No Abstract] [Full Text] [Related]
37. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
Philis-Tsimikas A
Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus.
Hussain S; Chowdhury TA
Drugs; 2019 Feb; 79(3):231-242. PubMed ID: 30742277
[TBL] [Abstract][Full Text] [Related]
39. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
40. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
